Industry Insights: Genomic Testing for Early-Stage Breast Cancer
William Audeh, Chief Medical Officer at Agendia, discusses recent data supporting genomic testing results in guiding clinical decision-making
Clinical Scorecard: Industry Insights: Genomic Testing for Early-Stage Breast Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Early-stage breast cancer |
| Key Mechanisms | Genomic assays inform treatment decisions by assessing tumor biology rather than solely relying on traditional clinicopathologic factors. |
| Target Population | Patients with HR+/HER2- early-stage breast cancer |
| Care Setting | Oncology clinics and surgical settings |
Key Highlights
- Genomic assays redefine adjuvant decision-making, identifying patients who benefit from chemotherapy.
- The MINDACT trial shows genomic low-risk HR+/HER2- patients do not benefit from adjuvant chemotherapy.
- Genomic profiling predicts response to neoadjuvant therapy and informs surgical planning.
- NCCN guidelines now recognize genomic testing for neoadjuvant decision-making.
- Genomic insights help balance treatment intensity with quality-of-life considerations.
Guideline-Based Recommendations
Diagnosis
- Use histopathologic assessment alongside genomic testing for comprehensive tumor evaluation.
Management
- Personalize treatment regimens based on genomic profiling results.
Monitoring & Follow-up
- Regularly assess treatment response and adjust based on genomic insights.
Risks
- Identify patients at high risk for recurrence to avoid overtreatment and unnecessary toxicities.
Patient & Prescribing Data
HR+/HER2- early-stage breast cancer patients
Genomic tests can determine the necessity of anthracycline-based chemotherapy and extended endocrine therapy.
Clinical Best Practices
- Incorporate genomic testing into treatment planning for HR+/HER2- breast cancer.
- Utilize genomic insights to guide surgical decisions and timing.
- Engage in discussions with patients about the implications of genomic results on treatment options.
References
